Aspen Neuroscience, Inc. has made a noteworthy update regarding its Chief Commercial Officer, Lisa Johnson-Pratt, in a recent SEC filing. This change is significant as it may affect the company's strategic direction and operations within the pharmaceutical preparations industry.

Background

Aspen Neuroscience, Inc. is a company focused on pharmaceutical preparations, with its primary operations based in San Diego, California. The firm trades under the ticker symbol ASPE and is listed on no specific exchange. The company was incorporated in Delaware and has an EIN of 831312969.

What the Filing Says

The recent filing, dated October 29, 2026, indicates that Lisa Johnson-Pratt holds the position of Chief Commercial Officer. The filing specifies that she currently has no securities owned but holds several stock options. For instance, she has stock options to purchase 40,477 shares at an exercise price of $7.42, which expire in 2034.

Impact

This update may impact various stakeholders, including employees, investors, and competitors. As the pharmaceutical industry evolves, changes in leadership can lead to shifts in company strategy, potentially influencing market dynamics and competition.

What's Next

The filing does not say what happens next.

Additional Details on Stock Options

In addition to the stock options to purchase 40,477 shares at an exercise price of $7.42, Lisa Johnson-Pratt also holds two other significant stock options. One option allows her to purchase another 40,477 shares at an exercise price of $8.70, which will expire on December 10, 2034. The second option grants her the right to buy 65,775 shares at an exercise price of $5.74, expiring on November 25, 2035. These options reflect her potential for significant equity participation in Aspen Neuroscience, Inc.

Vesting Schedule

The filing outlines specific vesting schedules for the stock options held by Johnson-Pratt. The option priced at $7.42 was granted on March 28, 2024, with 1/4th of the option vesting on January 16, 2025, and the remainder vesting monthly thereafter. The option at $8.70 was granted on December 11, 2024, with a similar vesting structure. The most recent option priced at $5.74, granted on November 26, 2025, will begin vesting monthly starting December 20, 2025. This structured vesting is designed to incentivize her continued service with the company.

Power of Attorney

The filing also includes a Power of Attorney, executed by Lisa Johnson-Pratt, which designates Jeffrey L. Boerneke as her Attorney-in-Fact. This document grants him the authority to act on her behalf in matters related to SEC filings, including submitting forms and maintaining her EDGAR account. This delegation of authority is a common practice to ensure compliance with regulatory requirements.

Company Information

Aspen Neuroscience, Inc. operates under the Central Index Key (CIK) number 0002124080 and is classified under the Standard Industrial Classification (SIC) code for pharmaceutical preparations (2834). The company is incorporated in Delaware and has its business address at 10835 Road to the Cure, Suite 100, San Diego, CA 92121. This location is indicative of its focus on life sciences and biotechnology.